MX395106B - Celulas t alogenicas específicas de wt1 y usos de las mismas. - Google Patents

Celulas t alogenicas específicas de wt1 y usos de las mismas.

Info

Publication number
MX395106B
MX395106B MX2018002816A MX2018002816A MX395106B MX 395106 B MX395106 B MX 395106B MX 2018002816 A MX2018002816 A MX 2018002816A MX 2018002816 A MX2018002816 A MX 2018002816A MX 395106 B MX395106 B MX 395106B
Authority
MX
Mexico
Prior art keywords
methods
multiple myeloma
treating multiple
cell leukemia
human patient
Prior art date
Application number
MX2018002816A
Other languages
English (en)
Spanish (es)
Other versions
MX2018002816A (es
Inventor
Guenther Koehne
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2018002816A publication Critical patent/MX2018002816A/es
Publication of MX395106B publication Critical patent/MX395106B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2018002816A 2015-09-10 2016-09-09 Celulas t alogenicas específicas de wt1 y usos de las mismas. MX395106B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US201562220641P 2015-09-18 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (2)

Publication Number Publication Date
MX2018002816A MX2018002816A (es) 2018-06-08
MX395106B true MX395106B (es) 2025-03-21

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002816A MX395106B (es) 2015-09-10 2016-09-09 Celulas t alogenicas específicas de wt1 y usos de las mismas.

Country Status (14)

Country Link
US (1) US20190381098A1 (enExample)
EP (1) EP3347028A1 (enExample)
JP (1) JP6947720B2 (enExample)
KR (1) KR20180048992A (enExample)
CN (1) CN108348552A (enExample)
AU (1) AU2016320877A1 (enExample)
CA (1) CA2997757A1 (enExample)
HK (1) HK1257882A1 (enExample)
IL (1) IL257929B2 (enExample)
MX (1) MX395106B (enExample)
RU (1) RU2743381C2 (enExample)
TW (1) TWI759270B (enExample)
WO (1) WO2017044678A1 (enExample)
ZA (1) ZA201801656B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
AU2013207669C1 (en) * 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
JP6947720B2 (ja) 2021-10-13
JP2018530534A (ja) 2018-10-18
IL257929B2 (en) 2024-06-01
TWI759270B (zh) 2022-04-01
CN108348552A (zh) 2018-07-31
MX2018002816A (es) 2018-06-08
US20190381098A1 (en) 2019-12-19
AU2016320877A1 (en) 2018-04-19
HK1257882A1 (zh) 2019-11-01
ZA201801656B (en) 2022-12-21
WO2017044678A1 (en) 2017-03-16
RU2018112526A (ru) 2019-10-10
RU2018112526A3 (enExample) 2020-01-31
TW201714619A (zh) 2017-05-01
IL257929A (en) 2018-05-31
RU2743381C2 (ru) 2021-02-17
EP3347028A1 (en) 2018-07-18
KR20180048992A (ko) 2018-05-10
IL257929B1 (en) 2024-02-01
CA2997757A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
EP4527922A3 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CO2018004937A2 (es) Células asesinas naturales y células ilc3 y usos de las mismas
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX378273B (es) Compuestos activos hacia bromodominios.
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
MX2017015186A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
GB2531952A (en) SC-ß cells and compositions and methods for generating the same
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
BR112017000464A2 (pt) células gama delta t e uso das mesmas
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
MX373176B (es) Donadores de nitroxilo con indice terapeutico mejorado.
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
MX395106B (es) Celulas t alogenicas específicas de wt1 y usos de las mismas.
MX2015013784A (es) C. novyi para el tratamiento de tumores solidos en humanos.
BR112019000837A2 (pt) células miméticas de célula b
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t